Continuing Treatment in Postmenopausal Women with Osteoporosis
NOVEMBER 13, 2016
During the 2016 ACR/ARHP meeting, Lori Fitzpatrick, MD, explained, "It's interesting, that even though we were head to head with another anabolic agent, we actually had better increases in BMD at cortical sites (total hip and the femoral hip), than teriparatide, and we also had reduction in fractures. However, we actually had a 43% reduction in non vertebral fractures compared to placebo." According to Fitzpatrick, additional findings showed that, regardless of age, whether or not patients had vertebral or non-vertebral fractures, treatment with abaloparatide worked.